FDA will hold a public workshop on Dec. 6 to discuss development of therapies for hemophilia, including new efficacy endpoints. The agency plans to develop patient-reported outcomes for hemophilia trials and discuss pediatric enrollment, long-term safety assessments and measurements for factor VIII and IX levels in gene therapy trials.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,